Abbott, Celera Genomics, PerkinElmer, Nonlinear Dynamics, Agilent, Proteome Systems, MorphoSys Antibodies by Design, JPT Peptide Technologies, MolPAGE, Blueprint Initiative, GE, Lilly, Dharmacon | GenomeWeb

Abbott Selects Two Antigen Targets from Celera Genomics for Cancer Therapeutic Development

Celera Genomics announced last week that two of its antigen targets have been selected for further investigation by Abbott Laboratories for cancer therapeutic development.

The targets were developed by Celera Genomics over the last year, since the company signed a collaboration agreement (see PM 7/16/2004) with Abbott to use proteomic technologies to develop cell surface antigens that could serve as cancer therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.